ROUND EIGHT RESULTS, BY COUNTRY
Author:
Bernard Rivers
Article Type:Article Number: 2
ABSTRACT A detailed listing and analysis is provided of which Round 8 proposals have been approved.
Based on advice from the TRP, the Board divided eligible Round 8 proposals into five Categories, as follows:
- Category 1: Approved proposals requiring no or minor clarifications, which need to be provided within 8 weeks and then given a final approval by the TRP Chair and/or Vice-Chair.
- Category 2: Proposals that are approved in principle, subject to the required clarifications being provided within a limited timeframe (6 weeks for the applicant to provide an initial detailed response to the TRP queries, and a further 3 months to obtain the final TRP approval should further clarifications be requested). The TRP Chair and Vice-Chair need to give final approval.
- Category 2B: Proposals that are treated as those in Category 2, but are regarded as being relatively weak, on grounds of technical merit and/or issues of feasibility and likelihood of effective implementation.
- Category 3: Proposals not approved in their present form, though applicants are encouraged to resubmit in Round 9 following major revision.
- Category 4: Proposals that are rejected, with applicants not encouraged to resubmit in any similar form.
The Board approved “in principle” (to use its precise words) all proposals in Categories 1, 2 and 2B. However, some of the approvals are immediate and some are delayed, depending on future availability of funds. The prioritization is handled as follows:
- Category 1 proposals are approved immediately.
- Each country submitting a Category 2 or 2B proposal is assigned a disease burden index of 4 or 1 according to whether the disease burden is “very high” or not “very high”. And each such country is assigned a poverty index of 4, 2 or 0 according to whether the country is low income, lower-middle income, or upper-middle income. The sum of these two indexes creates the Composite Index, whose value is therefore between 8 and 1. The higher the country’s Composite Index, the sooner its Category 2 or 2B proposal will be approved.
- Category 2 proposals with a Composite Index of 8, 6 or 5 are immediately approved.
- Remaining Category 2 and 2B proposals will be approved in the following order, as pledges by donors to the Fund become available in the course of 2008-9:
1. Category 2, Composite Index 3
2. Category 2B, Composite Index 8
3. Category 2B, Composite Index 6
4. Category 2B, Composite Index 5
5. Category 2B, Composite Index 3
The number of Round 8 grants per Category and Composite Index are as follows:
Table 4: Round 8 results by Category and Composite Index
|
Category and Composite Index |
Number of proposals |
Amount requested |
| Immediate approval: Category 1 |
16 |
USD 0.45 b. |
| Immediate approval: Category 2, Composite Index 8, 6 or 5 |
43 |
USD 1.68 b. |
| Delayed approval: Category 2, Composite Index 3 |
8 |
USD 0.18 b. |
| Delayed approval: Category 2B, Composite Index 8 |
6 |
USD 0.44 b. |
| Delayed approval: Category 2B, Composite Index 6 |
6 |
USD 0.10 b. |
| Delayed approval: Category 2B, Composite Index 5 |
8 |
USD 0.13 b. |
| Delayed approval: Category 2B, Composite Index 3 |
7 |
USD 0.09 b. |
| Subtotal: All Approved Proposals: |
94 |
USD 3.06 b. |
| Not Approved: Category 3 |
63 |
USD 1.75 b. |
| Not Approved: Category 4 |
17 |
USD 0.43 b. |
| Not Approved: Removed sub-components of approved proposals |
n/a |
USD 0.56 b. |
| Subtotal: All Non-Approved Proposals: |
80 |
USD 2.73 b. |
| Total: All Proposals |
174 |
USD 5.79 b. |
Round 8 results by applicant were as in Tables 5 and 6, below.
Table 5: Round 8 Results, by Country
|
Country |
Disease component |
Applicant |
Decision |
Category (defined above) |
Composite Index (defined above) |
Amount requested |
Amount requested |
| Afghanistan | Malaria (disease part + HSS part) |
CCM |
Delayed approval |
2B |
5 |
EUR 30,075,545 |
EUR 55,397,259 |
| Afghanistan | TB |
CCM |
Immediate approval |
1 |
n/a |
EUR 7,394,272 |
EUR 22,669,094 |
| Algeria | HIV |
CCM |
Not approved |
4 |
n/a |
USD 15,252,168 |
USD 32,720,961 |
| Angola | HIV |
CCM |
Not approved |
4 |
n/a |
USD 75,142,046 |
USD 235,955,998 |
| Angola | TB |
CCM |
Not approved |
4 |
n/a |
USD 11,756,766 |
USD 25,098,444 |
| Armenia | HIV (HSS part) |
CCM |
Immediate approval |
2 |
6 |
EUR 1,466,930 |
EUR 2,062,995 |
| Armenia | HIV (disease part) |
CCM |
Not approved |
n/a |
n/a |
EUR 2,394,212 |
EUR 6,257,962 |
| Armenia | TB |
CCM |
Immediate approval |
1 |
n/a |
EUR 2,006,371 |
EUR 6,205,708 |
| Bangladesh | HIV |
CCM |
Not approved |
3 |
n/a |
USD 14,964,866 |
USD 48,892,309 |
| Bangladesh | Malaria |
CCM |
Not approved |
3 |
n/a |
USD 22,729,707 |
USD 68,436,372 |
| Bangladesh | TB (disease part + HSS part) |
CCM |
Immediate approval |
2 |
8 |
USD 5,627,763 |
USD 77,430,875 |
| Belarus | HIV (disease part + HSS part) |
CCM |
Immediate approval |
1 |
n/a |
EUR 11,120,812 |
EUR 25,389,385 |
| Belarus | TB |
CCM |
Not approved |
3 |
n/a |
EUR 14,254,281 |
EUR 31,226,265 |
| Benin | Malaria |
CCM |
Not approved |
3 |
n/a |
EUR 26,909,499 |
EUR 26,909,499 |
| Benin | TB |
CCM |
Not approved |
3 |
n/a |
EUR 3,556,947 |
EUR 6,658,804 |
| Bolivia | HIV |
CCM |
Not approved |
3 |
n/a |
USD 7,763,930 |
USD 23,802,395 |
| Bolivia | Malaria |
CCM |
Delayed approval |
2B |
3 |
USD 6,744,407 |
USD 15,578,630 |
| Bolivia | TB |
CCM |
Not approved |
4 |
n/a |
USD 9,191,385 |
USD 16,777,841 |
| Bosnia & Herzegovina | HIV |
CCM |
Not approved |
3 |
n/a |
EUR 12,336,077 |
EUR 29,441,571 |
| Bosnia & Herzegovina | TB |
CCM |
Not approved |
3 |
n/a |
EUR 5,722,028 |
EUR 9,796,973 |
| Brazil | HIV |
CCM |
Not approved |
3 |
n/a |
EUR 9,372,000 |
EUR 30,000,000 |
| Brazil | Malaria |
CCM |
Delayed approval |
2 |
3 |
EUR 20,659,117 |
EUR 42,023,909 |
| Brazil | TB |
CCM |
Not approved |
3 |
n/a |
EUR 40,191,174 |
EUR 80,560,970 |
| Bulgaria | TB |
CCM |
Delayed approval |
2B |
3 |
EUR 3,661,435 |
EUR 10,527,766 |
| Burkina Faso | HIV |
CCM |
Not approved |
3 |
n/a |
EUR 24,844,539 |
EUR 48,473,676 |
| Burkina Faso | Malaria |
CCM |
Immediate approval |
2 |
8 |
EUR 53,120,303 |
EUR 63,203,438 |
| Burkina Faso | TB (disease part + HSS part) |
CCM |
Delayed approval |
2B |
8 |
EUR 12,045,997 |
EUR 27,167,685 |
| Burundi | HIV |
CCM |
Delayed approval |
2B |
8 |
USD 41,315,145 |
USD 159,105,087 |
| Cambodia | HIV |
CCM |
Not approved |
3 |
n/a |
USD 38,283,888 |
USD 134,514,948 |
| Cambodia | TB (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
USD 11,449,113 |
USD 34,686,505 |
| Cameroon | HIV |
CCM |
Not approved |
3 |
n/a |
EUR 28,961,003 |
EUR 66,797,527 |
| Cameroon | TB |
CCM |
Not approved |
3 |
n/a |
EUR 7,015,400 |
EUR 13,782,656 |
| Cape Verde | HIV |
CCM |
Delayed approval |
2 |
3 |
USD 5,321,184 |
USD 12,578,727 |
| Central African Republic | Malaria |
CCM |
Immediate approval |
2 |
8 |
EUR 10,871,833 |
EUR 30,971,995 |
| Central African Republic | TB |
CCM |
Not approved |
3 |
n/a |
EUR 9,742,228 |
EUR 22,482,120 |
| Chad | HIV |
CCM |
Immediate approval |
2 |
8 |
EUR 29,702,927 |
EUR 63,244,477 |
| Chad | TB |
CCM |
Delayed approval |
2B |
8 |
EUR 3,427,453 |
EUR 5,385,007 |
| China | HIV |
CCM |
Immediate approval |
2 |
6 |
EUR 15,747,191 |
EUR 44,128,188 |
| China | Malaria |
CCM |
Not approved |
3 |
n/a |
EUR 29,681,060 |
EUR 61,332,628 |
| China | TB |
CCM |
Delayed approval |
2B |
6 |
EUR 24,012,517 |
EUR 87,664,363 |
| Colombia | HIV |
CCM |
Not approved |
3 |
n/a |
EUR 12,254,560 |
EUR 32,867,073 |
| Colombia | Malaria |
CCM |
Delayed approval |
2 |
3 |
EUR 16,997,092 |
EUR 32,262,166 |
| Colombia | TB |
CCM |
Not approved |
3 |
n/a |
EUR 11,968,726 |
EUR 22,919,271 |
| Comoros | HIV |
CCM |
Not approved |
4 |
n/a |
EUR 1,235,586 |
EUR 2,229,001 |
| Comoros | Malaria (disease part) |
CCM |
Immediate approval |
2 |
5 |
EUR 5,280,932 |
EUR 11,788,954 |
| Comoros | Malaria (HSS part) |
CCM |
Not approved |
n/a |
n/a |
EUR 1,061,171 |
EUR 2,834,024 |
| Congo (Democratic Republic of) | HIV |
CCM |
Immediate approval |
2 |
8 |
USD 79,225,696 |
USD 262,911,091 |
| Congo (Democratic Republic of) | Malaria |
CCM |
Immediate approval |
2 |
8 |
USD 153,997,553 |
USD 393,102,357 |
| Congo (Democratic Republic of) | TB (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
USD 71,422,674 |
USD 199,682,709 |
| Congo (Republic of) | Malaria |
CCM |
Delayed approval |
2B |
6 |
EUR 25,465,537 |
EUR 54,135,175 |
| Congo (Republic of) | TB |
CCM |
Delayed approval |
2B |
6 |
EUR 2,303,089 |
EUR 5,005,041 |
| Cote d’Ivoire | HIV (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
EUR 55,758,904 |
EUR 142,745,182 |
| Cote d’Ivoire | Malaria |
CCM |
Immediate approval |
2 |
8 |
EUR 139,365,869 |
EUR 180,298,316 |
| Cote d’Ivoire | TB |
CCM |
Not approved |
3 |
n/a |
EUR 7,152,767 |
EUR 17,886,903 |
| Djibouti | Malaria |
CCM |
Not approved |
3 |
n/a |
EUR 4,335,600 |
EUR 10,391,353 |
| Djibouti | TB |
CCM |
Not approved |
4 |
n/a |
EUR 3,912,029 |
EUR 8,688,954 |
| Dominican Republic | Malaria |
CCM |
Delayed approval |
2 |
3 |
USD 4,492,517 |
USD 8,703,257 |
| Ecuador | HIV |
CCM |
Not approved |
3 |
n/a |
USD 14,389,246 |
USD 35,615,171 |
| Ecuador | Malaria |
CCM |
Delayed approval |
2 |
3 |
USD 8,374,965 |
USD 15,108,812 |
| Ecuador | TB |
CCM |
Not approved |
3 |
n/a |
USD 14,066,522 |
USD 32,819,024 |
| Eritrea | HIV (disease part) |
CCM |
Immediate approval |
2 |
8 |
USD 17,071,740 |
USD 45,135,676 |
| Eritrea | HIV (HSS part) |
CCM |
Not approved |
n/a |
n/a |
USD 6,087,808 |
USD 14,939,526 |
| Ethiopia | Malaria (disease part + HSS part) |
CCM |
Immediate approval |
1 |
n/a |
USD 148,412,502 |
USD 291,064,713 |
| Fiji | TB (disease part + HSS part) |
CCM |
Delayed approval |
2B |
3 |
USD 4,789,119 |
USD 9,929,474 |
| Gabon | HIV |
CCM |
Immediate approval |
1 |
n/a |
EUR 6,879,029 |
EUR 17,006,207 |
| Gabon | Malaria |
CCM |
Not approved |
3 |
n/a |
EUR 5,030,319 |
EUR 13,851,883 |
| Gambia | HIV (disease part + HSS part) |
CCM |
Immediate approval |
2 |
5 |
EUR 15,250,763 |
EUR 36,582,801 |
| Ghana | HIV |
CCM |
Immediate approval |
2 |
8 |
USD 51,498,200 |
USD 99,858,800 |
| Ghana | Malaria (disease part) |
CCM |
Immediate approval |
2 |
8 |
USD 39,639,118 |
USD 158,030,372 |
| Ghana | Malaria (HSS part) |
CCM |
Not approved |
n/a |
n/a |
USD 4,462,500 |
USD 13,420,570 |
| Guatemala | HIV (disease part + HSS part) |
CCM |
Not approved |
4 |
n/a |
EUR 37,104,756 |
EUR 115,595,987 |
| Guatemala | Malaria |
CCM |
Not approved |
3 |
n/a |
EUR 21,586,329 |
EUR 41,174,990 |
| Guinea-Bissau | TB (HSS part) |
CCM |
Immediate approval |
2 |
5 |
EUR 595,684 |
EUR 1,286,514 |
| Guinea-Bissau | TB (disease part) |
CCM |
Not approved |
n/a |
n/a |
EUR 7,818,909 |
EUR 21,213,426 |
| Guyana | HIV (HSS part) |
CCM |
Immediate approval |
2 |
6 |
USD 4,637,491 |
USD 10,094,303 |
| Guyana | HIV (disease part) |
CCM |
Not approved |
n/a |
n/a |
USD 6,005,402 |
USD 18,370,517 |
| Guyana | Malaria |
CCM |
Not approved |
3 |
n/a |
USD 2,993,178 |
USD 5,573,355 |
| Guyana | TB |
CCM |
Delayed approval |
2B |
3 |
USD 3,087,615 |
USD 7,125,899 |
| Haiti | Malaria |
CCM |
Delayed approval |
2B |
5 |
USD 33,402,457 |
USD 50,046,179 |
| Haiti | TB (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
USD 31,167,222 |
USD 59,742,348 |
| Honduras | HIV |
CCM |
Not approved |
3 |
n/a |
USD 5,334,334 |
USD 13,389,159 |
| Honduras | TB (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
USD 8,031,166 |
USD 16,170,525 |
| India | HIV |
CCM |
Not approved |
3 |
n/a |
EUR 21,263,481 |
EUR 75,212,496 |
| India | Malaria |
CCM |
Not approved |
3 |
n/a |
EUR 39,883,180 |
EUR 100,310,326 |
| India | TB |
CCM |
Not approved |
3 |
n/a |
EUR 32,420,155 |
EUR 79,915,954 |
| Indonesia | HIV |
CCM |
Immediate approval |
1 |
n/a |
USD 45,384,545 |
USD 130,653,560 |
| Indonesia | Malaria |
CCM |
Delayed approval |
2 |
3 |
USD 73,453,889 |
USD 120,092,536 |
| Indonesia | TB |
CCM |
Immediate approval |
1 |
n/a |
USD 28,106,251 |
USD 93,001,059 |
| Iran | HIV |
CCM |
Delayed approval |
2B |
6 |
USD 10,328,021 |
USD 32,354,404 |
| Kazakhstan | HIV |
CCM |
Not approved |
3 |
n/a |
USD 13,880,664 |
USD 35,851,200 |
| Kazakhstan | Malaria |
CCM |
Not approved |
4 |
n/a |
USD 897,612 |
USD 1,376,877 |
| Kazakhstan | TB |
CCM |
Delayed approval |
2B |
3 |
USD 37,557,518 |
USD 69,880,919 |
| Kenya | HIV |
CCM |
Not approved |
4 |
n/a |
USD 105,743,946 |
USD 129,929,146 |
| Kenya | Malaria |
CCM |
Not approved |
3 |
n/a |
USD 89,634,705 |
USD 200,581,638 |
| Kenya | TB (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
USD 41,216,118 |
USD 137,406,953 |
| Korea (Democratic People’s Republic of) | HIV |
CCM |
Not approved |
3 |
n/a |
EUR 15,119,159 |
EUR 28,699,056 |
| Korea (Democratic People’s Republic of) | Malaria |
CCM |
Immediate approval |
2 |
5 |
EUR 9,542,511 |
EUR 18,348,551 |
| Korea (Democratic People’s Republic of) | TB |
CCM |
Delayed approval |
2B |
5 |
EUR 17,686,423 |
EUR 47,102,407 |
| Kyrgyz Republic | HIV |
Sub-CCM |
Not approved |
4 |
n/a |
USD 3,560,042 |
USD 6,770,643 |
| Kyrgyz Republic | Malaria |
CCM |
Immediate approval |
2 |
5 |
USD 4,530,888 |
USD 8,788,180 |
| Kyrgyz Republic | TB |
CCM |
Not approved |
3 |
n/a |
USD 7,507,988 |
USD 24,622,765 |
| Lao People’s Democratic Republic | HIV (disease part + HSS part) |
CCM |
Immediate approval |
2 |
8 |
USD 9,114,326 |
USD 24,569,609 |
| Lesotho | HIV (disease part + HSS part) |
CCM |
Immediate approval |
2 |
6 |
USD 39,773,696 |
USD 103,429,628 |
| Lesotho | TB |
CCM |
Delayed approval |
2B |
6 |
USD 10,967,381 |
USD 28,083,618 |
| Liberia | HIV (disease part + HSS part) |
CCM |
Immediate approval |
2 |
8 |
USD 20,199,587 |
USD 78,235,151 |
| Madagascar | HIV |
CCM |
Immediate approval |
2 |
5 |
USD 11,768,300 |
USD 36,037,600 |
| Madagascar | TB |
CCM |
Delayed approval |
2B |
5 |
USD 8,987,239 |
USD 22,797,620 |
| Mali | HIV (disease part) |
CCM |
Immediate approval |
2 |
8 |
EUR 40,526,846 |
EUR 126,634,447 |
| Mali | HIV (HSS part) |
CCM |
Not approved |
n/a |
n/a |
EUR 21,852,585 |
EUR 49,979,708 |
| Mauritania | HIV (HSS part) |
CCM |
Immediate approval |
1 |
n/a |
USD 2,772,376 |
USD 3,942,505 |
| Mauritania | HIV (disease part) |
CCM |
Not approved |
n/a |
n/a |
USD 9,367,617 |
USD 22,266,256 |
| Mauritius | HIV |
CCM |
Immediate approval |
1 |
n/a |
EUR 4,052,662 |
EUR 7,890,632 |
| Moldova | HIV |
CCM |
Delayed approval |
2B |
6 |
EUR 8,606,392 |
EUR 16,723,816 |
| Moldova | TB |
CCM |
Immediate approval |
1 |
n/a |
EUR 5,281,042 |
EUR 13,322,904 |
| Mozambique | HIV (HSS part) |
CCM |
Immediate approval |
2 |
8 |
USD 13,177,452 |
USD 34,874,346 |
| Mozambique | HIV (disease part) |
CCM |
Not approved |
n/a |
n/a |
USD 39,073,131 |
USD 170,770,762 |
| Mozambique | Malaria |
CCM |
Not approved |
3 |
n/a |
USD 78,152,630 |
USD 210,466,897 |
| Namibia | HIV |
CCM |
Not approved |
3 |
n/a |
USD 64,688,284 |
USD 160,505,034 |
| Nepal | HIV (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
USD 35,249,649 |
USD 90,220,063 |
| Nicaragua | HIV |
CCM |
Delayed approval |
2 |
3 |
USD 31,385,337 |
USD 65,390,510 |
| Nigeria | HIV (HSS part) |
CCM |
Immediate approval |
2 |
8 |
USD 75,055,363 |
USD 178,030,052 |
| Nigeria | HIV (disease part) |
CCM |
Not approved |
n/a |
n/a |
USD 293,867,577 |
USD 831,612,641 |
| Nigeria | Malaria |
CCM |
Delayed approval |
2B |
8 |
USD 334,351,033 |
USD 599,810,494 |
| Nigeria | TB |
CCM |
Not approved |
3 |
n/a |
USD 42,169,586 |
USD 181,584,855 |
| Pakistan | HIV |
CCM |
Not approved |
3 |
n/a |
USD 18,636,708 |
USD 66,219,051 |
| Pakistan | TB |
CCM |
Immediate approval |
2 |
8 |
USD 9,810,559 |
USD 26,682,133 |
| Panama | HIV |
CCM |
Not approved |
3 |
n/a |
USD 4,949,840 |
USD 13,592,440 |
| Papua New Guinea | Malaria |
CCM |
Immediate approval |
2 |
5 |
USD 70,139,822 |
USD 152,252,244 |
| Paraguay | HIV (disease part) |
CCM |
Immediate approval |
2 |
6 |
EUR 4,765,763 |
EUR 13,314,074 |
| Paraguay | HIV (HSS part) |
CCM |
Not approved |
n/a |
n/a |
EUR 1,514,597 |
EUR 3,267,216 |
| Paraguay | Malaria |
CCM |
Not approved |
3 |
n/a |
EUR 4,403,483 |
EUR 8,558,518 |
| Paraguay | TB |
CCM |
Not approved |
3 |
n/a |
EUR 8,277,793 |
EUR 18,576,825 |
| Peru | HIV (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
EUR 30,545,347 |
EUR 50,546,403 |
| Peru | TB |
CCM |
Immediate approval |
1 |
n/a |
EUR 11,484,622 |
EUR 22,229,143 |
| Philippines | HIV (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
EUR 25,581,667 |
EUR 42,391,843 |
| Russian Federation | TB |
CCM |
Not approved |
3 |
n/a |
EUR 65,687,022 |
EUR 139,199,580 |
| Russian Federation | TB (disease part + HSS part) |
Sub-CCM |
Not approved |
4 |
n/a |
EUR 18,808,972 |
EUR 33,180,557 |
| Rwanda | HIV |
CCM |
Not approved |
3 |
n/a |
USD 15,591,988 |
USD 38,979,970 |
| Rwanda | Malaria (disease part) |
CCM |
Immediate approval |
2 |
5 |
USD 58,567,001 |
USD 138,469,243 |
| Rwanda | Malaria (HSS part) |
CCM |
Not approved |
n/a |
n/a |
USD 33,702,875 |
USD 48,541,601 |
| Sao Tome and Principe | HIV |
CCM |
Not approved |
3 |
n/a |
USD 568,464 |
USD 1,529,157 |
| Sao Tome and Principe | TB |
CCM |
Immediate approval |
1 |
n/a |
USD 1,132,914 |
USD 2,608,818 |
| Senegal | HIV (disease part + HSS part) |
CCM |
Not approved |
3 |
n/a |
EUR 54,507,488 |
EUR 136,440,454 |
| Senegal | TB |
CCM |
Not approved |
3 |
n/a |
EUR 6,930,243 |
EUR 17,791,333 |
| Serbia | HIV |
CCM |
Delayed approval |
2 |
3 |
EUR 3,766,988 |
EUR 12,406,231 |
| Solomon Islands | HIV (disease part) |
CCM |
Not approved |
n/a |
n/a |
USD 4,570,062 |
USD 10,472,323 |
| Solomon Islands | HIV (HSS part) |
CCM |
Delayed approval |
2B |
5 |
USD 845,725 |
USD 1,686,884 |
| Solomon Islands | TB |
CCM |
Delayed approval |
2B |
5 |
USD 3,608,714 |
USD 7,334,716 |
| Somalia | HIV (disease part + HSS part) |
Non-CCM |
Immediate approval |
2 |
5 |
USD 25,669,049 |
USD 60,261,684 |
| South Africa | HIV |
CCM |
Not approved |
3 |
n/a |
USD 91,680,358 |
USD 259,056,796 |
| South Africa | TB |
CCM |
Not approved |
4 |
n/a |
USD 68,229,369 |
USD 194,670,986 |
| Sri Lanka | Malaria |
CCM |
Delayed approval |
2B |
3 |
USD 24,040,444 |
USD 40,915,151 |
| Sudan (Northern Sector) | TB (disease part + HSS part) |
CCM |
Delayed approval |
2B |
8 |
USD 17,979,663 |
USD 58,048,795 |
| Sudan (Southern Sector) | HIV (disease part + HSS part) |
Sub-CCM |
Not approved |
3 |
n/a |
USD 28,482,979 |
USD 124,015,542 |
| Swaziland | HIV (HSS part) |
CCM |
Immediate approval |
2 |
6 |
USD 8,180,726 |
USD 15,136,442 |
| Swaziland | HIV (disease part) |
CCM |
Not approved |
n/a |
n/a |
USD 49,055,285 |
USD 90,214,010 |
| Swaziland | Malaria |
CCM |
Immediate approval |
1 |
n/a |
USD 5,637,713 |
USD 13,880,938 |
| Swaziland | TB |
CCM |
Immediate approval |
2 |
6 |
USD 4,785,540 |
USD 11,839,346 |
| Tajikistan | HIV |
CCM |
Immediate approval |
2 |
8 |
EUR 13,264,761 |
EUR 34,578,129 |
| Tajikistan | Malaria |
CCM |
Immediate approval |
2 |
5 |
EUR 5,224,796 |
EUR 9,615,246 |
| Tajikistan | TB (disease part + HSS part) |
CCM |
Immediate approval |
2 |
5 |
EUR 9,840,404 |
EUR 17,534,572 |
| Tanzania (United Republic of) | HIV (disease part) |
CCM |
Immediate approval |
2 |
8 |
USD 145,848,085 |
USD 598,106,619 |
| Tanzania (United Republic of) | HIV (HSS part) |
CCM |
Not approved |
n/a |
n/a |
USD 65,422,207 |
USD 96,794,019 |
| Tanzania (United Republic of) | Malaria |
CCM |
Immediate approval |
2 |
5 |
USD 111,586,404 |
USD 113,335,025 |
| Thailand | HIV |
CCM |
Immediate approval |
2 |
6 |
USD 38,254,259 |
USD 106,123,200 |
| Thailand | TB |
CCM |
Immediate approval |
1 |
n/a |
USD 12,420,804 |
USD 30,547,583 |
| Togo | HIV |
CCM |
Immediate approval |
2 |
8 |
EUR 31,775,839 |
EUR 81,340,190 |
| Tunisia | TB |
CCM |
Delayed approval |
2B |
3 |
USD 4,400,014 |
USD 7,560,548 |
| Turkmenistan | TB |
CCM |
Not approved |
3 |
n/a |
USD 10,649,147 |
USD 20,279,651 |
| Ukraine | TB |
CCM |
Not approved |
3 |
n/a |
USD 36,251,905 |
USD 94,715,697 |
| Uruguay | HIV |
CCM |
Not approved |
3 |
n/a |
USD 8,951,242 |
USD 21,393,157 |
| Uzbekistan | HIV |
CCM |
Not approved |
3 |
n/a |
USD 26,428,887 |
USD 79,669,868 |
| Uzbekistan | Malaria |
CCM |
Delayed approval |
2B |
5 |
USD 2,789,923 |
USD 6,144,821 |
| Uzbekistan | TB |
CCM |
Delayed approval |
2B |
5 |
USD 13,881,631 |
USD 56,124,183 |
| Vietnam | HIV |
CCM |
Immediate approval |
2 |
8 |
USD 14,577,204 |
USD 48,693,061 |
| West Bank and Gaza | TB |
Non-CCM |
Immediate approval |
1 |
n/a |
EUR 972,386 |
EUR 2,152,074 |
| Yemen | HIV |
CCM |
Not approved |
3 |
n/a |
USD 6,495,225 |
USD 25,735,775 |
| Yemen | TB |
CCM |
Not approved |
4 |
n/a |
USD 6,767,022 |
USD 19,880,527 |
| Zambia | HIV (disease part + HSS part) |
CCM |
Immediate approval |
1 |
n/a |
USD 144,079,863 |
USD 307,273,164 |
| Zanzibar | HIV |
CCM |
Not approved |
4 |
n/a |
EUR 4,127,078 |
EUR 7,274,018 |
| Zanzibar | Malaria (disease part + HSS part) |
CCM |
Immediate approval |
2 |
5 |
EUR 5,648,340 |
EUR 12,355,905 |
| Zimbabwe | HIV |
CCM |
Immediate approval |
2 |
8 |
USD 86,821,730 |
USD 296,752,070 |
| Zimbabwe | Malaria (disease part + HSS part) |
CCM |
Immediate approval |
2 |
5 |
USD 70,994,472 |
USD 141,316,927 |
| Zimbabwe | TB |
CCM |
Delayed approval |
2B |
8 |
USD 29,538,652 |
USD 58,298,297 |
Table 6: Round 8 results for regional applicants
|
Country |
Disease |
Applicant |
Decision |
Category |
Composite Index |
Requested |
Requested |
| CARE (India, Nepal, Bangladesh) | HIV |
Regional organization |
Not approved |
4 |
n/a |
EUR 14,145,331 |
EUR 40,817,080 |
| CCLAB (Guatemala, El Salvador, Honduras, Nicaragua, Dom. Rep., Panama, Costa Rica, Belize) | HIV |
Regional Coordinating Mechanism |
Not approved |
4 |
n/a |
USD 20,292,270 |
USD 46,811,258 |
| COPRECOS LAC (Colombia, El Salvador, Nicaragua, Panama, Paraguay, Dom. Rep., Uruguay, Argentina, Belize, Brazil, Ecuador, Guatemala, Haiti, Honduras, Peru, Chile, Costa Rica, Venezuela) | HIV |
Regional organization |
Not approved |
3 |
n/a |
USD 23,122,297 |
USD 68,666,796 |
| GLIA (Burundi, DRC, Kenya, Rwanda, Tanzania, Uganda) | HIV |
Regional organization |
Not approved |
4 |
n/a |
USD 10,824,037 |
USD 27,044,765 |
| SADC (Angola, Botswana, Namibia, Zambia, Zimbabwe) | Malaria (disease part + HSS part) |
Regional Coordinating Mechanism |
Not approved |
3 |
n/a |
USD 36,018,686 |
USD 86,985,372 |
